The upcoming report from Phibro Animal Health (PAHC Quick QuotePAHC - Free Report) is expected to reveal quarterly earnings of $0.72 per share, indicating an increase of 26.3% compared to the year-ago period. Analysts forecast revenues of $366.14 million, representing a decline of 3.3% year over year.

The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.

Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.

While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.

With that in mind, let's delve into the average projections of some Phibro metrics that are commonly tracked and projected by analysts on Wall Street.

Analysts predict that the 'Net Sales- Animal Health' will reach $283.35 million. The estimate points to a change of -3.1% from the year-ago quarter.

According to the collective judgment of analysts, 'Net Sales- Mineral Nutrition' should come in at $64.77 million. The estimate indicates a year-over-year change of +1%.

Analysts expect 'Net Sales- Animal Health- Vaccines' to come in at $38.82 million. The estimate suggests a change of +0.6% year over year.

The consensus estimate for 'Net Sales- Animal Health- MFAs and other' stands at $196.75 million. The estimate indicates a year-over-year change of -4.7%.

The consensus among analysts is that 'Net Sales- Animal Health- Nutritional specialties' will reach $47.79 million. The estimate indicates a change of +0.9% from the prior-year quarter.

The combined assessment of analysts suggests that 'Net Sales- Performance Products' will likely reach $18.02 million. The estimate indicates a change of -18.3% from the prior-year quarter.

The average prediction of analysts places 'Net Sales by Region- Latin America and Canada' at $71.40 million. The estimate indicates a year-over-year change of -15.1%.

Analysts forecast 'Net Sales by Region- Europe, Middle East and Africa' to reach $53.70 million. The estimate points to a change of -6.8% from the year-ago quarter.

The collective assessment of analysts points to an estimated 'Net Sales by Region- United States' of $203.34 million. The estimate suggests a change of +0.7% year over year.

Analysts' assessment points toward 'Net Sales by Region- Asia Pacific' reaching $31.72 million. The estimate indicates a change of -9.5% from the prior-year quarter.

Based on the collective assessment of analysts, 'Adjusted EBITDA- Animal Health' should arrive at $61.41 million. The estimate is in contrast to the year-ago figure of $60.58 million.

It is projected by analysts that the 'Adjusted EBITDA- Performance Products' will reach $2.29 million. The estimate compares to the year-ago value of $3.03 million.

Over the past month, shares of Phibro have returned +3.4% versus the Zacks S&P 500 composite's +2.8% change. Currently, PAHC carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .